Cria: A Potential Drug Target Or Biomarker (G81553)

Target Name: CYRIA

NCBI ID: G81553

CYRIA

Cria: A Potential Drug Target Or Biomarker

Cyria (FLJ33961) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a member of the tyrosine kinase family and is involved in the regulation of cellular processes that are essential for growth, development, and survival. The identification and characterization of cyria as a potential drug target or biomarker has significant implications for the development of new therapeutic approaches for a variety of diseases.

Chemical Characterization
Cria is a 21-kDa protein that is expressed in the brain, heart, liver, and kidney. It is highly conserved across species and has a calculated pI of 5.9. Cria is a protein that is involved in the regulation of several cellular processes, including cell growth, differentiation, and survival. It is a member of the tyrosine kinase family and is involved in the signaling pathway that regulates cell proliferation and survival.

Expression and Localization
Cria is highly expressed in various tissues of the body, including the brain, heart, liver, and kidney. It is expressed in the brain and is detected in the nuclei of neurons and glial cells. It is also expressed in the hearts, where it is detected in the intermyocardial muscle and in the endocardium. In the liver, it is expressed in the hepatocytes and is involved in the regulation of cellular processes that are essential for liver function. In the kidneys, it is expressed in the podocytes and is involved in the regulation of water and electrolyte balance.

Function and Interaction
Cria is involved in several cellular processes that are essential for growth, development, and survival. It is a key regulator of cell proliferation and survival, and it is involved in the regulation of angiogenesis, inflammation, and cellular signaling. It is a member of the tyrosine kinase family and is involved in the signaling pathway that regulates cell proliferation and survival. It plays a role in the regulation of cellular processes that are essential for the development and maintenance of tissues and organs, including the brain, heart, liver, and kidney.

Clinical Significance
The identification and characterization of cyria as a potential drug target or biomarker has significant implications for the development of new therapeutic approaches for a variety of diseases. The regulation of cellular processes that are essential for growth, development, and survival by cyria is a key aspect of many diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Therefore, the development of new therapeutic approaches that target cyria may have a significant impact on the treatment of these diseases.

Drugs that Target Cria
The development of drugs that target cyria is an active area of research, and there is significant interest in the use of small molecules and other compounds that can modulate the activity of cyria. One of the potential strategies for targeting cyria is the use of inhibitors of tyrosine kinase activity, such as inhibitors of the activity of the Fyn protein, which is a key regulator of tyrosine kinase activity.

Another approach that is being explored is the use of small molecules that can modulate the activity of cyria is the use of inhibitors of the PI3K/AKT signaling pathway, which is a key regulator of cellular processes that are essential for growth, development, and survival. The PI3K/AKT signaling pathway is involved in the regulation of angiogenesis, inflammation, and cellular signaling, and it is a potential target for the development of new therapeutic approaches for diseases that are characterized by the uncontrolled regulation of this pathway.

Conclusion
Cria is a protein that is involved in the regulation of several cellular processes that are essential for growth, development, and survival. Its high conservation across species and the calculation of its pI make it a potential drug target or biomarker. The identification and characterization of cyria as a potential drug target or biomarker has significant implications for the development of new therapeutic approaches for a variety of diseases. The development of drugs that target cyria is an

Protein Name: CYFIP Related Rac1 Interactor A

Functions: May negatively regulate RAC1 signaling and RAC1-driven cytoskeletal remodeling (Probable). May regulate chemotaxis, cell migration and epithelial polarization by controlling the polarity, plasticity, duration and extent of protrusions (Probable)

The "CYRIA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYRIA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets